Larvol Delta - AlloNK174-an-Allogeneic-Nongenetically-Modified-Cord-Bloodderived-NK-Cell-Therapy-in-Combination-With-Rituximab-Studied-in-Relapsing-Forms-of-Bcell-Dependent-Rheumatologic-Diseases

AlloNK (GCC4001) - Artiva Biotherapeutics

Rituxan (rituximab) - Roche

http://clinicaltrials.gov/ct2/show/NCT06991114

Apr 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next